Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
about
sameAs
Computational neuropsychiatry - schizophrenia as a cognitive brain network disorderNeuropeptide S attenuates neuropathological, neurochemical and behavioral changes induced by the NMDA receptor antagonist MK-801.Glutamate-mediated excitotoxicity in schizophrenia: a review.Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology.Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome.Effects of ketamine exposure on dopamine concentrations and dopamine type 2 receptor mRNA expression in rat brain tissue.Psychosis: atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty?A prototypical Sigma-1 receptor antagonist protects against brain ischemia.Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.Successful management of dexmedetomidine for postoperative intensive care sedation in a patient with anti-NMDA receptor encephalitis: a case report and animal experiment.Comparison of the efficacy of two anticonvulsants, phenytoin and valproate to improve PCP and d-amphetamine induced deficits in a reversal learning task in the rat.Ketamine: NMDA Receptors and Beyond.NMDA receptor function, memory, and brain aging.Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection.Chronic treatment with caffeine blunts the hyperlocomotor but not cognitive effects of the N-methyl-D-aspartate receptor antagonist MK-801 in mice.Proton MRS in twin pairs discordant for schizophrenia.Impaired glutamine metabolism in NMDA receptor hypofunction induced by MK801.Global meta-analysis of the C-11377G alteration in the ADIPOQ gene indicates the presence of population-specific effects: challenge for global health initiatives.Maternal mentalization affects mothers' - but not children's - weight via emotional eating.Genetic variation in COMT and PRODH is associated with brain anatomy in patients with schizophrenia.No correlation between body mass index and striatal dopamine transporter availability in healthy volunteers using SPECT and [123I]PE2I.
P2860
Q22241226-182584CC-AC7A-4CD6-A5F2-E4285B1714D6Q22241226-8B66FFBC-A7A0-4687-9B79-CEE65C93F3A4Q30477912-C58D6E57-E5B2-4D3F-8F21-650AAE2B5D61Q30477912-D0838A01-95E5-4DF0-BC6B-1AE1AB051623Q30845062-00199BA3-ACA8-4563-BE47-89EE9FF17CAFQ30845062-E19DD106-3374-42E2-9146-94208E965C2CQ31153621-0ABEEFDB-9F76-4E8B-AE9A-EFF495B42BB7Q31153621-5A3C71E5-ED23-4D98-9F90-6151E4CE736EQ34348231-A48D9B5F-F6B1-426D-A134-25937AAE67C0Q36046542-D55EDE13-1127-4260-889F-38406E5B9923Q36046542-E87829D9-2136-4EFE-84B0-B38314AE646FQ36784624-A29D3D08-9033-45CE-9B77-8982B22BADA5Q36784624-A5E936DA-0754-43BC-AE33-2329D689B64FQ36976939-539F212C-3534-4B2C-8A41-B7B386312DA0Q36976939-9ADA8C29-1D74-4A02-80C6-EE2CB6903A54Q36998808-339D757F-E3D9-4E81-9F5F-8E4357F2B65CQ36998808-C77E5059-9C59-40C0-A3E7-640970C249A0Q37194871-6DADB39C-8C65-437A-89DD-8772E4B4CD09Q37194871-D828FD21-9005-4127-BD9B-8C139AAFD1ABQ37240818-7F696CDB-08CE-4BC6-85B1-EF5176FC9296Q37240818-BFA0ECBA-ED6F-4FE6-B890-A044096E0B9EQ37490388-14A0C512-9ABD-4200-9E58-B79E47E0F6ABQ37490388-A8E654F0-0D15-4A5B-8CBA-7D947AC00E68Q38578480-3B0529DF-2BF1-43FA-8312-CEC65C77C6B6Q38578480-7190BE50-A1D3-4CF5-A193-6F78AEA6F7D8Q38669576-0B6E2DA0-86D2-416A-8468-A4F4A2AD9C8CQ38669576-F1C2BBD2-CCF9-4604-98FA-71C95DBBB6ECQ38743350-7DC17343-B3B7-41CB-9C65-7CB8E16F431BQ38743350-904FD11C-D234-4F27-A1F8-75F859544522Q44317537-D244BDCD-FA3C-4191-AC47-CA15EBB17C06Q46470298-CE8C1178-2E82-4AD0-831A-95CE211B5688Q46619889-B519BE04-952A-46E2-8965-17024CB2F3C2Q46954857-A234B553-C615-48C7-BB6C-7C36072064FEQ47294512-C5067E06-5448-47F7-930B-EF71360BC8E7Q48167083-3804AB54-CFF2-46D2-A2BC-E99E88265F1CQ50972237-0A266472-D90D-4686-9900-411DEC2C1A77
P2860
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
@ast
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
@en
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
@nl
type
label
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
@ast
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
@en
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
@nl
altLabel
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity
@en
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity
@nl
prefLabel
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
@ast
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
@en
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
@nl
P2093
P2860
P1433
P1476
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity
@en
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity.
@en
P2093
Dikranian K
K Dikranian
N B Farber
P2860
P2888
P356
10.1038/SJ.MP.4001912
10.1038/SJ/MP/4000912
P407
P577
2002-01-01T00:00:00Z